

# Clinical Neurological Society of America 51st Annual Meeting: Contemporary Neurology 2025

- January 18-21, 2025 in Clearwater, FL



- “This activity is jointly provided by Global Education Group and [Clinical Neurological Society of America](#).”
- This activity is supported by an educational grant from argenx US Inc., Avadel CNS Pharmaceuticals, LLC., Boston Scientific, Eisai Inc. and Grifols.

## **PROGRAM MATERIALS REQUIREMENTS**

### **Target Audience**

The CNSA Annual Meeting is designed to provide practicing neurologists with the most up-to-date information for the diagnosis and management of patients with neurologic conditions.

This meeting is designed primarily for practicing neurologists. Other health care providers that can benefit from this meeting include residents, fellows, physician assistants, nurse practitioners, nurses, neurosurgeons, psychiatrists, social workers, doctors of pharmacy and neuropsychologists.

### **Statement of Need/Program Overview**

To be more capable of practicing at the standard of care, neurologists benefit from a better understanding of emerging diagnosis and treatment options for neuromuscular diseases; autonomic dysfunction; headache disorders; neuroimmunology conditions including autoimmune encephalitis; epilepsy; sleep disorders; stroke; Alzheimer’s disease; cerebral amyloid angiopathy; neuro-oncology; and concussion. They also need a better understanding of the latest strategies for monitoring pediatric and adult patients with these conditions, the impact of social and structural inequities which contribute to cognitive decline in aging populations and approaches to promoting a more inclusive and equitable environment in neurology. This educational activity is designed to improve understanding and use of current clinical practice guidelines and recent research findings in the participant’s practice.

### **Educational Objectives**

- Identify newly approved and emerging treatment options for various neurological diseases, including Pompe disease, hATTR amyloidosis, SOD1 amyotrophic lateral sclerosis, adult spinal muscular atrophy, Duchene muscular dystrophy, and myasthenia gravis
- Describe the rationale of ongoing treatment trials for various neurological diseases, including FSHD, Myotonic Dystrophy, Becker muscular dystrophy, and CIDP.
- Explain the latest diagnostic approaches and treatment options for autonomic failure and dysfunction, including autonomic failure occurring in movement disorders such as Parkinson disease and multiple system atrophy as well as peripheral nerve disorders such as diabetes and autonomic dysfunction in postural tachycardia syndrome.

- Discuss the latest research on the immune system's role in neurological disorders including updates on the novel CNS demyelinating diseases, MOG antibody disease, and autoimmune encephalitis.
- Discuss the challenges for managing late-onset epilepsy patients.
- Discuss the considerations for managing epilepsy in pregnant women.
- Describe recent advances and emerging tools in stroke prevention, diagnosis, treatment modalities, and rehabilitation strategies.
- Explain new tools for diagnosing Alzheimer disease
- Discuss the latest research on monoclonal antibodies in the treatment and prevention of Alzheimer disease.
- Identify recent advances in the diagnosis and treatment of brain tumors.
- Discuss contemporary methods for diagnosing and managing concussions
- Compare the advantages and limitations of treatment options for sleep disorders including insomnia, narcolepsy and sleep apnea.
- Discuss recent advancements in the diagnosis and management of different types of headache disorders.
- Describe the importance of diversity and inclusion in clinician education and healthcare as it relates to the benefits in patient care.
- Compare the benefits and risks of using multiple medications with differing mechanisms of action for the treatment of Parkinson disease.
- Analyze the impact of social factors (e.g., social isolation, access to care, socioeconomic status) and develop strategies to address social and structural inequities that contribute to cognitive decline in aging populations.
- Review the use of deep brain stimulation (DBS) for the treatment of movement disorders
- Compare the potential benefits and limitations of traditional DBS compared with new adaptive DBS (aDBS) devices and therapies.

## **Faculty**

**Bassam Bassam**  
**Charleston, Larry**  
**Cherian, Laurel**  
**Chetkovich, Dane**  
**Conyers, Frank Garrett**  
**Desjardins, Annick**  
**Hassell, Travis**  
**Hickenbottom, Suzy**  
**Houghton, David**  
**Johnson, Emily**  
**Kraus, Nina**  
**Liu, Andy**

**Mulukutla, Sarah**  
**Okun, Michael**  
**Peltier, Amanda**  
**Posas, Jose**  
**Rose, Deborah**  
**Ruffing, Kyle**  
**Shah, Suma**  
**Smith, Gordon**  
**Spector, Andrew**  
**Subramony, Sub**  
**Zallek, Sarah**  
**Zinn, Erin**

## **Program Agenda**

[Please click to view the scientific program.](#)

## **Physician Accreditation Statement**



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Clinical Neurological Society of America. Global is accredited by the ACCME to provide continuing medical education for physicians.

## **Physician Credit Designation**

Global Education Group designates this live activity for a maximum of 21.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## **Global Contact Information**

For information about the accreditation of this program, please contact Global at 303-395-1782 or [cme@globaleducationgroup.com](mailto:cme@globaleducationgroup.com).

## **Instructions for Obtaining Credit**

Participants of the live event will be able to claim *AMA PRA Category 1 Credits™*. In order to receive credit, participants must complete the meeting evaluation and credit claim application following the conclusion of the event. A link to the survey will be emailed to participants at the email address provided during registration. Statements of participation or credit will be emailed by Global Education Group, CNSA's CME provider, 4-6 weeks following the program.

## **System Requirement**

### **PC**

1.4 GHz Intel Pentium 4 or faster processor (or equivalent)  
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)  
512 MB of RAM (1 GB recommended)  
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome  
For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)

### **MAC**

1.83 GHz Intel Core Duo or faster processor  
512 MB of RAM (1 GB recommended)  
MAC OS X 10.12, 10.13 and 10.14  
Mozilla Firefox, Apple Safari, Google Chrome  
For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)

## **Fee Information & Refund/Cancellation Policy**

[Please click here to view the fee information.](#)

Registration can be refunded in full by November 22. If cancelled after November 22, a 50% partial refund will be accommodated. To request a refund, please contact Nina Perez, [nina@neuroamerica.org](mailto:nina@neuroamerica.org).

## **Disclosures of Relevant Financial Relationships**

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The **faculty** have the following relevant financial relationships with ineligible companies:

<b>Bassam Bassam</b>	<p><b>Consulting Fee (e.g., Advisory Board)</b> UCB Pharma Company, Alexion Pharmaceuticals</p> <p><b>Speakers' Bureau</b> UCB Pharma Company</p>
<b>Charleston, Larry</b>	<p><b>Consulting Fee (e.g., Advisory Board)</b> Allergan/AbbVie, Amgen, Amneal, Aurene, Biohaven, Haleon, LinPharma, Pfizer, Satsuma</p> <p><b>Contracted Research (Principal Investigators must provide information, even if received by the institution)</b> Amgen</p> <p><b>Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed)</b> Mi-Helper Inc.</p>
<b>Cherian, Laurel</b>	Nothing to Disclose
<b>Chetkovich, Dane</b>	Nothing to Disclose
<b>Conyers, Frank Garrett</b>	Nothing to Disclose
<b>Desjardins, Annick</b>	<p><b>Consulting Fee (e.g., Advisory Board)</b> Biodexa Pharmaceuticals PLC Orbus Therapeutics, Inc</p> <p><b>Contracted Research (Principal Investigators must provide information, even if received by the institution)</b> Orbus Therapeutics, Inc Biodexa Pharmaceuticals PLC Exvade Bioscience Inc</p> <p><b>Speakers' Bureau</b> Chimerix Inc</p> <p><b>Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed)</b> Istari Oncology</p>
<b>Hassell, Travis</b>	<b>Consulting Fee (e.g., Advisory Board):</b> Medtronic, Inc, Boston Scientific, Inc
<b>Hickenbottom, Suzy</b>	Nothing to Disclose
<b>Houghton, David</b>	Nothing to Disclose
<b>Johnson, Emily</b>	Nothing to Disclose
<b>Kraus, Nina</b>	Nothing to Disclose
<b>Liu, Andy</b>	<b>Consulting Fee (e.g., Advisory Board)</b> Lucent

<b>Mulukutla, Sarah</b>	Nothing to Disclose
<b>Okun, Michael</b>	Nothing to Disclose
<b>Peltier, Amanda</b>	<b>Consulting Fee (e.g., Advisory Board)</b> Alnylam, Astrazeneca, Argenx, CSL Behring, Alexion <b>Contracted Research (Principal Investigators must provide information, even if received by the institution)</b> CSL Behring <b>Speakers' Bureau</b> Astrazeneca, Alnylam
<b>Posas, Jose</b>	<b>Consulting Fee (e.g., Advisory Board)</b> Pfizer, Abbvie
<b>Rose, Deborah</b>	Nothing to Disclose
<b>Ruffing, Kyle</b>	<b>Contracted Research (Principal Investigators must provide information, even if received by the institution)</b> Edgewise Therapeutics.
<b>Shah, Suma</b>	<b>Consulting Fee (e.g., Advisory Board)</b> TG Therapeutics <b>Contracted Research (Principal Investigators must provide information, even if received by the institution)</b> Novartis
<b>Smith, Gordon</b>	<b>Consulting Fee (e.g., Advisory Board)</b> Alexion, Argenx, Eidos, Lilly, UCB, Kriya, Sangano, Seismic, Lexicon <b>Contracted Research (Principal Investigators must provide information, even if received by the institution)</b> Cour <b>Speakers' Bureau</b> Alexion, UCB
<b>Spector, Andrew</b>	Nothing to Disclose
<b>Subramony, Sub</b>	<b>Consulting Fee (e.g., Advisory Board)</b> Reata, Biogen, Avidity, Fulcrums, Amicus, Larimar <b>Contracted Research (Principal Investigators must provide information, even if received by the institution)</b> Reata, Retrotope, PTC, Larimar, Biohaven, Avidity, Fulcrums, Reneo, Vertex, Arthrex
<b>Zallek, Sarah</b>	Nothing to Disclose
<b>Zinn, Erin</b>	Nothing to Disclose

The ***planners and managers*** have the following relevant financial relationships with ineligible companies:

The planners and managers at Global Education Group have no relevant financial relationships to disclose.

The planners and managers at Clinical Neurological Society of America have no relevant financial relationships to disclose.

### **Disclosure of Unlabeled Use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Clinical Neurological Society of America do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

**Disclaimer**

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.